DHEA-S: How to Interpret Your Lab Result as a Woman

What DHEA-S Actually Is (and Why It Is Different from DHEA)

DHEA-S stands for dehydroepiandrosterone sulfate. It is the sulfated, water-soluble storage form of DHEA, and roughly 95 percent of it comes directly from the adrenal cortex, with minimal ovarian contribution. That adrenal specificity is the whole reason clinicians prefer it over DHEA itself for lab testing: DHEA fluctuates throughout the day and surges with ACTH pulses, while DHEA-S has a much longer half-life of 15 to 30 hours and stays stable enough to measure reliably from a single morning blood draw.

DHEA-S serves as a reservoir. Your peripheral tissues, including skin, breast, and adipose, convert it into testosterone and estrogen locally. This local conversion matters more in postmenopausal women, whose ovarian estrogen production has stopped, and it partly explains why DHEA-S is studied as a marker of tissue-level androgen and estrogen availability even after menopause.

How It Differs from Total Testosterone and Free Testosterone

When you have signs of androgen excess, your clinician will typically check a panel: total testosterone, free testosterone, DHEA-S, and sometimes androstenedione and 17-hydroxyprogesterone. DHEA-S is the one test that points almost exclusively toward the adrenal gland. A high total testosterone with a normal DHEA-S steers the workup toward the ovary. A high DHEA-S with a modestly elevated total testosterone steers it toward the adrenal gland. The Endocrine Society's 2018 guideline on androgen excess recommends DHEA-S as part of the initial biochemical screen whenever adrenal pathology is suspected.

Why the Lab Reference Range Printed on Your Report May Not Fit You

Every laboratory sets its own reference interval. Two women, same age, same result, could both be flagged as "normal" by one lab and "high" by another. Age-stratified ranges exist, but not all labs apply them correctly. When you look at your result, always check the lab's age-specific column, not the generic adult female range. If your report shows a single adult female range, ask your clinician to interpret your number against a published age-stratified table.

Normal DHEA-S Ranges for Women Across Life Stages

DHEA-S levels are among the most age-dependent values in endocrinology. A level that is perfectly normal at 25 would be frankly elevated at 60, and a level normal at 60 might look low on a report designed for a 25-year-old. The ranges below come from a large reference interval study published in the Journal of Clinical Endocrinology and Metabolism, and are expressed in micrograms per deciliter (mcg/dL). Your lab may report in micromoles per liter; to convert, divide mcg/dL by 36.1.

| Life Stage | Approximate DHEA-S Range (mcg/dL) | |---|---| | Adolescence (15-19 yrs) | 65-380 | | Reproductive years (20-34 yrs) | 98-430 | | Mid-reproductive (35-44 yrs) | 60-335 | | Perimenopause (45-54 yrs) | 35-265 | | Early postmenopause (55-64 yrs) | 18-205 | | Late postmenopause (65+ yrs) | 10-170 |

These are population-derived approximations. Clinical decisions depend on trend over time, symptoms, and the full hormone panel, not a single number in isolation.

The Adrenopause Concept

Adrenal DHEA-S output drops by approximately 10 percent per decade starting in your late twenties. By the time you reach your seventies, circulating DHEA-S may be only 10 to 20 percent of your peak value. This physiological decline is sometimes called "adrenopause," a parallel, if less dramatic, shift to menopause. It is a normal part of aging, not a disease, though researchers continue to study whether partial supplementation improves quality of life in older women. A Cochrane review from 2015 found only modest and inconsistent benefits from DHEA supplementation in postmenopausal women and did not endorse routine use.

What a High DHEA-S Result Means

A DHEA-S above the age-appropriate upper limit almost always points to excess adrenal androgen production. The clinical question is: why?

Mild Elevation (10-50 Percent Above Upper Limit)

Mild elevations are the most common scenario in clinical practice and often reflect one of the following:

• Functional adrenal hyperandrogenism associated with PCOS. Roughly 20 to 30 percent of women with PCOS have a mildly elevated DHEA-S, reflecting dysregulated adrenal androgen secretion alongside the more typical ovarian androgen excess. The ovary is still the primary driver in most PCOS, but the adrenal component matters for treatment planning.
• Stress and HPA-axis activation. Acute physical or psychological stress raises ACTH, which temporarily pushes DHEA-S up. A single elevated result during an illness or a period of severe stress may not reflect your baseline.
• Medication effects. Valproate (used for epilepsy and sometimes bipolar disorder) is associated with DHEA-S elevation. Metformin, paradoxically, may lower it slightly in women with PCOS.
• Non-classic congenital adrenal hyperplasia (NCAH). NCAH due to 21-hydroxylase deficiency can present in adolescence or young adulthood with acne, irregular periods, and hirsutism, and is often accompanied by DHEA-S elevation alongside a markedly elevated 17-hydroxyprogesterone. ACOG Practice Bulletin No. 182 notes NCAH in the differential for androgen excess, and the Endocrine Society recommends a morning 17-OHP level to screen for it.

Marked Elevation (More Than Double the Upper Limit)

A DHEA-S above roughly 700-800 mcg/dL in a reproductive-age woman, or any value substantially above age-adjusted norms, warrants urgent evaluation for an adrenal androgen-secreting tumor. These tumors are rare but important to exclude. Adrenocortical carcinoma typically produces very high DHEA-S alongside cortisol and other steroids, and rapid symptom onset (new hirsutism over weeks rather than years) is a clinical red flag regardless of the absolute number. Adrenal imaging, typically CT of the abdomen and pelvis, is the next step for significantly elevated values.

Cushing Syndrome and DHEA-S

Counter-intuitively, Cushing syndrome due to a cortisol-secreting adrenal adenoma may actually suppress DHEA-S, because the tumor produces cortisol autonomously while high cortisol suppresses ACTH, which then suppresses the zone of the adrenal that makes DHEA-S. In pituitary Cushing disease, ACTH is high, so DHEA-S may be elevated or normal. This distinction matters when interpreting a cortisol-DHEA-S pair.

What a Low DHEA-S Result Means

Low DHEA-S is common and, in most women, represents normal physiological aging or medication effect rather than disease. The exception is when it falls low in a younger woman or when other adrenal markers are also low.

Low DHEA-S in Reproductive-Age Women

In a woman under 40 with DHEA-S below the age-appropriate lower limit, consider:

• Exogenous glucocorticoid use. Inhaled, topical, oral, or injected corticosteroids all suppress ACTH and therefore DHEA-S. Even moderate-dose inhaled fluticasone used daily for asthma can measurably suppress adrenal DHEA-S output over months.
• Primary or secondary adrenal insufficiency. Addison disease and hypopituitarism both reduce DHEA-S. If you have fatigue, salt craving, low blood pressure, or hyperpigmentation, a low DHEA-S adds to the clinical picture. A morning cortisol and ACTH stimulation test are the definitive next steps, not DHEA-S supplementation.
• Hyperprolactinemia. Elevated prolactin, whether from a pituitary adenoma or medication, can suppress adrenal androgen output. A study in the Journal of Clinical Endocrinology and Metabolism showed lower DHEA-S in hyperprolactinemic women compared to controls.

Low DHEA-S in Perimenopause and Postmenopause

After menopause, a low DHEA-S is statistically normal and does not by itself require treatment. The question of whether supplementing it improves sexual function, bone density, or cognition remains open. The 2023 Menopause Society Position Statement on nonhormone therapies does not endorse DHEA-S testing or systemic DHEA supplementation as standard menopause care. Intravaginal prasterone (Intrarosa), a prescription DHEA product applied locally, is FDA-approved specifically for dyspareunia due to menopause-related genitourinary syndrome (GSM), but its mechanism is local, and it does not meaningfully raise serum DHEA-S.

DHEA-S in PCOS: What the Connection Looks Like

PCOS is the most common reason a reproductive-age woman gets a DHEA-S test. The Rotterdam criteria do not require DHEA-S to be elevated for a PCOS diagnosis, and most PCOS-related androgen excess comes from the ovary (reflected by total and free testosterone). Still, adrenal hyperandrogenism co-exists in a meaningful minority of PCOS patients.

A practical clinical framework: if your total testosterone is elevated but your DHEA-S is normal, your androgen excess is probably ovarian and responds well to combined oral contraceptives or spironolactone. If both are elevated, the adrenal component may need separate attention, and suppression with low-dose dexamethasone (0.25-0.5 mg nightly) is sometimes used short-term in women with proven adrenal hyperandrogenism planning fertility treatment. This combined-source framework is not described as a distinct decision tree in most published guidelines, but it reflects a clinically practical way to match the source of androgen excess to the treatment target.

A 2022 meta-analysis in Fertility and Sterility found that DHEA-S elevation in PCOS correlates with a more metabolically unfavorable phenotype, including higher fasting insulin and a greater risk of metabolic syndrome, independent of BMI. This means a high DHEA-S in PCOS is not just a cosmetic concern. It is a signal to look harder at insulin resistance and cardiovascular risk.

DHEA-S Across Reproductive Transitions

Trying to Conceive

In women with diminished ovarian reserve, some fertility clinics prescribe oral DHEA supplementation (75 mg daily) to improve ovarian response before IVF. A 2015 Cochrane review of DHEA for poor ovarian responders found insufficient high-quality evidence to confirm benefit, though several small randomized trials suggested improved live birth rates. ASRM does not currently endorse routine DHEA supplementation for poor ovarian response outside of clinical trials. If your clinician recommends it, ask for DHEA-S monitoring to avoid over-supplementation, which can impair oocyte quality.

Pregnancy

DHEA-S levels drop during the first trimester and remain low throughout pregnancy. This is physiological: the placenta uses maternal and fetal adrenal DHEA-S as a substrate for estriol synthesis, rapidly clearing it from circulation. A low DHEA-S in a pregnant woman is expected and does not signal adrenal disease. Testing DHEA-S during pregnancy is rarely clinically indicated and the results are difficult to interpret without pregnancy-specific reference intervals.

Oral DHEA supplements are not established as safe in pregnancy and should be stopped before conception or immediately upon a positive pregnancy test. Androgenic compounds carry theoretical risk of virilizing a female fetus. No adequate human studies confirm safety, and the FDA pregnancy labeling system does not classify OTC supplements, so caution defaults to avoidance.

Lactation

DHEA-S does transfer into breast milk to a limited degree. Given the absence of safety data on supplemental DHEA during lactation, standard clinical practice is to avoid it while breastfeeding. The intravaginal prasterone product (Intrarosa) carries a label noting that it has not been studied in lactating women.

Perimenopause

DHEA-S declines in parallel with, but independently of, ovarian estrogen decline during perimenopause. Some women in their mid-to-late forties notice new fatigue, low libido, or worsening skin and hair quality alongside a falling DHEA-S. Whether these symptoms are driven by estrogen loss, DHEA-S loss, or both is genuinely hard to disentangle. A longitudinal cohort study from the Study of Women's Health Across the Nation (SWAN) showed that adrenal androgens including DHEA-S decline significantly across the menopause transition independently of FSH and estradiol trajectories.

Who Should Have DHEA-S Tested

DHEA-S testing is most clinically meaningful in the following situations:

• You have signs of androgen excess: hirsutism, acne, male-pattern hair thinning, or clitoral enlargement.
• You are being evaluated for PCOS and your clinician wants to characterize the androgen source.
• You have irregular periods and elevated total testosterone, and the source (ovarian vs. Adrenal) is unclear.
• You are being evaluated for possible adrenal insufficiency.
• You have a known or suspected adrenal mass.
• You are pursuing IVF and your clinic is evaluating ovarian reserve adjuncts.

Routine DHEA-S testing as a "wellness screen" or "anti-aging panel" is not endorsed by the Endocrine Society or ACOG. The test adds clinical value when there is a specific question to answer.

How to Lower DHEA-S When It Is Elevated

The right strategy depends entirely on the cause.

Treat the Underlying Cause First

If DHEA-S is elevated because of NCAH, low-dose glucocorticoid suppression (typically hydrocortisone 10-20 mg/day in divided doses, or low-dose dexamethasone) can normalize adrenal androgen output. For PCOS with adrenal involvement, combined oral contraceptives reduce LH-driven androgen stimulation and also modestly suppress adrenal DHEA-S through indirect mechanisms. Spironolactone, a commonly used anti-androgen in women, does not directly lower DHEA-S but blocks its downstream androgenic effect at the receptor level.

Lifestyle Factors

Chronic psychological stress drives cortisol and ACTH, which in turn stimulate DHEA-S. Evidence for stress reduction lowering DHEA-S specifically is thin, but managing cortisol burden through sleep, exercise, and stress reduction is good adrenal hygiene regardless. Sleep deprivation acutely raises cortisol. A study in the Journal of Clinical Endocrinology and Metabolism found that even partial sleep restriction significantly altered adrenal hormone profiles in young women.

What Does Not Work

Herbal supplements marketed to "balance cortisol" or "support the adrenals" have no peer-reviewed evidence for specifically lowering DHEA-S in androgen-excess states. Avoiding them and addressing the root cause is safer and more effective.

How to Raise DHEA-S When It Is Low

Before attempting to raise a low DHEA-S, confirm that the low level is actually causing the symptoms you are concerned about and that adrenal insufficiency has been excluded.

Prescription and OTC DHEA

In the United States, DHEA is sold OTC as a dietary supplement, which means it is not FDA-regulated for purity or potency. Doses in published studies for postmenopausal women range from 25 to 50 mg daily. A 12-month randomized controlled trial (NEJM 1994, Morales et al.) was among the first to show that oral DHEA at 50 mg daily raised serum DHEA-S to young-adult levels and modestly improved self-reported well-being in both men and women. Subsequent trials have shown inconsistent effects on libido, bone density, and cognition.

If you choose to supplement, have your DHEA-S checked 6 to 8 weeks after starting to confirm you are not over-replacing. Supraphysiologic DHEA-S from supplementation can convert to testosterone and cause acne, oily skin, and hair thinning, and can theoretically stimulate hormone-sensitive tissues.

Intravaginal Prasterone for GSM

If your primary concern is vaginal dryness and painful sex after menopause, intravaginal prasterone (Intrarosa, 6.5 mg nightly) is FDA-approved and acts locally in the vaginal tissue with minimal systemic absorption. It is not the same as raising systemic DHEA-S. This distinction matters if you or your clinician are concerned about systemic androgen exposure.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in DHEA supplementation trials. Most early studies enrolled both sexes or focused on older men. The few female-specific trials are small, short, and used heterogeneous outcome measures. Specifically:

• Long-term cardiovascular effects of DHEA supplementation in women are not established.
• Whether raising DHEA-S in perimenopausal women (who still have some endogenous production) provides benefit or harm compared to postmenopausal women is not studied.
• The interaction between DHEA supplementation and hormone therapy (estrogen with or without progesterone) has not been adequately characterized in randomized trials.

Acknowledging these gaps is part of giving you an accurate picture. What is extrapolated from general endocrinology may not apply precisely to your specific clinical situation.